Europska Unija - hrvatski - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - svi ostali terapeutski proizvodi - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Europska Unija - hrvatski - EMA (European Medicines Agency)

cis bio international - samarium (153sm) lexidronam pentasodium - pain; cancer - terapeutski radiofarmaceutski pripravci - quadramet je indiciran za olakšanje koštana bol u bolesnika s više bolno u tu svrhu koštanih metastaza koje zauzimaju tehnecij [99mtc]-s natpisom biphosphonates na kost skeniranja. dostupnost остеобластические metastaza, koje zauzimaju технеция [99мтс]-za označene biphosphonates mora biti potvrđena prije početka terapije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - ostali lijekovi protiv živčanog sustava - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastična sredstva - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - uklanjanje neuromuskularne blokade izazvane rokoronom ili vekuronomom. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - neuromuskularna blokada - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Europska Unija - hrvatski - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - циркониевые cyclosilicate korisnih natrija - hiperkalijemija - svi ostali terapeutski proizvodi - lokelma indiciran za liječenje гиперкалиемию kod odraslih pacijenata.